SCHEMBL67719

SCHEMBL67719

C[Si](C)(C)CCOCn1c(Br)nc(Br)c1Br

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.35
NPC1 O15118 1/20 0.32
PNP P00491 1/20 0.31
MYC P01106 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202648 0.87 PNP (0.31) DGAT1PNP
SCHEMBL5213310 0.85 DGAT1 (0.37) DGAT1NPC1MYC
SCHEMBL19404995 0.85 DGAT1 (0.37) DGAT1NPC1PNP
SCHEMBL23123528 0.82 DGAT1 (0.34) DGAT1NPC1
SCHEMBL67815 0.81 DGAT1 (0.35) DGAT1
SCHEMBL3637817 0.81 DGAT1 (0.33) DGAT1NPC1
SCHEMBL26965213 0.81 DGAT1 (0.33) DGAT1
SCHEMBL16660842 0.81 DGAT1 (0.43) DGAT1
SCHEMBL10358805 0.80 PNP (0.33) PNP
SCHEMBL1108608 0.80 DGAT1 (0.34) DGAT1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829559-B1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
US-20260035359-A1 HERBICIDAL IMIDAZOLE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2026-02-05 US disclosed
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 US disclosed
US-12365674-B2 Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection MERCK SHARP & DOHME LLC (US) 2025-07-22 US disclosed
US-12331044-B2 Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection MERCK SHARP & DOHME LLC (US) 2025-06-17 US disclosed
EP-4554933-A1 HERBICIDAL IMIDAZOLE COMPOUNDS Syngenta Crop Protection AG (CH) 2025-05-21 EP disclosed
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
CN-119451949-A Herbicidal imidazole compounds 先正达农作物保护股份公司 2025-02-14 CN disclosed
EP-3876928-B1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME LLC (US) 2024-10-23 EP disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
US-20050070588-A1 Imidazolyl inhibitors of 15-lipoxygenase BRISTOL-MYERS SQUIBB COMPANY 2005-03-31 US disclosed
EP-1224180-B1 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2003-07-02 EP disclosed
US-6579874-B2 P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives NOVARTIS AG (CH) 2003-06-17 US disclosed
EP-1224180-A2 SUBSTITUTED AZOLES Novartis AG (CH) 2002-07-24 EP disclosed
EP-0748314-B1 TETRASUBSTITUTED IMIDAZOLE DERIVATIVES, METHOD FOR PREPARING THE SAME, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AVENTIS PHARMA SA (FR) 2002-05-15 EP disclosed
US-20020049220-A1 Substituted azoles NOVARTIS AG (CH) 2002-04-25 US disclosed
WO-2000063204-A2 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2000-10-26 WO disclosed
US-5807878-A CARDIOVASCULAR DISORDERS Uclaf, Roussel (FR) 1998-09-15 US disclosed
EP-0748314-A1 NOVEL TETRASUBSTITUTED IMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, RESULTING NOVEL INTERMEDIATES, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ROUSSEL UCLAF (FR) 1996-12-18 EP disclosed
WO-1995023791-A1 NOVEL TETRASUBSTITUTED IMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, RESULTING NOVEL INTERMEDIATES, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME ROUSSEL UCLAF (FR) 1995-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035359-A1 HERBICIDAL IMIDAZOLE COMPOUNDS CBR3, CBR1, CLIC1 DGAT1 919/4885NPC1 733/4885PNP 4149/4885
US-12404274-B2 Macrocycles as factor xia inhibitors TFPI, TFPI2, F11 DGAT1 4152/4885NPC1 2027/4885PNP 4526/4885
US-20050070588-A1 Imidazolyl inhibitors of 15-lipoxygenase ALOX15, ALOX5, ALOX15B DGAT1 238/4885NPC1 909/4885PNP 2925/4885
US-12331044-B2 Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection HDAC1, HDAC11, HDAC10 DGAT1 4019/4885NPC1 1079/4885PNP 1018/4885
US-12365674-B2 Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection HDAC1, HDAC11, HDAC3 DGAT1 3991/4885NPC1 425/4885PNP 840/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 DGAT1 1931/4885NPC1 762/4885PNP 3667/4885
US-20020049220-A1 Substituted azoles MAPK1, MAPK4, MAP3K1 DGAT1 2618/4885NPC1 3073/4885PNP 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.